Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm ; volume:10 ; number:1 ; day:21 ; month:6 ; year:2023 ; pages:1-22 ; date:12.2023
EJNMMI Physics ; 10, Heft 1 (21.6.2023), 1-22, 12.2023
- Creator
-
Staanum, Peter Frøhlich
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40658-023-00561-8
- URN
-
urn:nbn:de:101:1-2023092209560262851018
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Staanum, Peter Frøhlich
- SpringerLink (Online service)
Other Objects (12)
![Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry](/assets/placeholder/searchResultMediaUnknown.png)
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT